Eagle Pharmaceuticals (EGRX) Competitors $3.55 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. BIOA, MOLN, ALEC, VTYX, LXEO, THTX, BDTX, ALTS, LYEL, and IKTShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), Lyell Immunopharma (LYEL), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Inhibikase Therapeutics BioAge Labs (NASDAQ:BIOA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability. Does the media prefer BIOA or EGRX? In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. BioAge Labs' average media sentiment score of 0.93 beat Eagle Pharmaceuticals' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media. Company Overall Sentiment BioAge Labs Positive Eagle Pharmaceuticals Neutral Is BIOA or EGRX more profitable? Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Eagle Pharmaceuticals N/A N/A N/A Which has preferable earnings and valuation, BIOA or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AEagle Pharmaceuticals$257.55M0.18$35.64MN/AN/A Do institutionals and insiders believe in BIOA or EGRX? 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryEagle Pharmaceuticals beats BioAge Labs on 4 of the 5 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.38M$838.34M$5.56B$9.10BDividend YieldN/A4.84%5.06%4.02%P/E RatioN/A1.3828.2620.26Price / Sales0.18241.37404.92152.16Price / Cash0.4017.6937.1257.67Price / BookN/A6.588.045.49Net Income$35.64M-$23.83M$3.19B$250.45M7 Day Performance18.33%1.59%3.62%4.79%1 Month Performance47.92%-0.08%5.98%9.59%1 Year Performance-41.03%4.35%29.39%16.41% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals2.4707 of 5 stars$3.55flatN/A-41.0%$23.38M$257.55M0.00100News CoverageGap DownBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/AMOLNMolecular Partners3.1212 of 5 stars$3.61-4.0%$12.00+232.4%-42.6%$151.81M$2.23M-1.88180ALECAlector3.8871 of 5 stars$1.44-4.6%$4.00+177.8%-70.9%$150.99M$100.56M-1.14270News CoverageVTYXVentyx Biosciences3.5134 of 5 stars$2.04-1.9%$10.00+390.2%+7.0%$148.01MN/A-1.1730News CoverageLXEOLexeo Therapeutics2.3591 of 5 stars$4.54+2.0%$16.60+265.6%-74.6%$147.73M$650K-1.3858High Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+118.8%$147.14M$85.87M-39.63140Earnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.7754 of 5 stars$2.50-3.1%$12.80+412.0%-49.2%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.1163 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.5057 of 5 stars$9.15-5.6%$15.00+63.9%-71.5%$143.49M$60K-0.37270Positive NewsIKTInhibikase Therapeutics1.2185 of 5 stars$1.93+2.1%$6.50+236.8%+27.1%$143.48MN/A-0.726 Related Companies and Tools Related Companies BIOA Alternatives MOLN Alternatives ALEC Alternatives VTYX Alternatives LXEO Alternatives THTX Alternatives BDTX Alternatives ALTS Alternatives LYEL Alternatives IKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
